OBJECTIVE: Although more than a dozen myositis-specific autoantibodies (MSAs) have been identified, most patients with myositis are positive for a single MSA. The specific overexpression of a given myositis autoantigen in myositis muscle has been proposed as initiating and/or propagating autoimmunity against that particular autoantigen. The present study was undertaken to test this hypothesis. METHODS: In order to quantify autoantigen RNA expression, RNA sequencing was performed on muscle biopsy samples from control subjects, MSA-positive patients with myositis, regenerating mouse muscles, and cultured human muscle cells. RESULTS: Muscle biopsy samples were available from 20 control subjects and 106 patients with autoantibodies recognizing hydroxymethylglutaryl-coenzyme A reductase (n = 40), signal recognition particles (n = 9), Jo-1 (n = 18), nuclear matrix protein 2 (n = 12), Mi-2 (n = 11), transcription intermediary factor 1γ (n = 11), or melanoma differentiation-associated protein 5 (n = 5). The increased expression of a given autoantigen in myositis muscle was not associated with autoantibodies recognizing that autoantigen (all q > 0.05). In biopsy specimens from both myositis muscle and regenerating mouse muscles, autoantigen expression correlated directly with the expression of muscle regeneration markers and correlated inversely with the expression of genes encoding mature muscle proteins. Myositis autoantigens were also expressed at high levels in cultured human muscle cells. CONCLUSION: Most myositis autoantigens are highly expressed during muscle regeneration, which may relate to the propagation of autoimmunity. However, factors other than overexpression of specific autoantigens are likely to govern the development of unique autoantibodies in individual patients with myositis.
OBJECTIVE: Although more than a dozen myositis-specific autoantibodies (MSAs) have been identified, most patients with myositis are positive for a single MSA. The specific overexpression of a given myositis autoantigen in myositis muscle has been proposed as initiating and/or propagating autoimmunity against that particular autoantigen. The present study was undertaken to test this hypothesis. METHODS: In order to quantify autoantigen RNA expression, RNA sequencing was performed on muscle biopsy samples from control subjects, MSA-positive patients with myositis, regenerating mouse muscles, and cultured human muscle cells. RESULTS: Muscle biopsy samples were available from 20 control subjects and 106 patients with autoantibodies recognizing hydroxymethylglutaryl-coenzyme A reductase (n = 40), signal recognition particles (n = 9), Jo-1 (n = 18), nuclear matrix protein 2 (n = 12), Mi-2 (n = 11), transcription intermediary factor 1γ (n = 11), or melanoma differentiation-associated protein 5 (n = 5). The increased expression of a given autoantigen in myositis muscle was not associated with autoantibodies recognizing that autoantigen (all q > 0.05). In biopsy specimens from both myositis muscle and regenerating mouse muscles, autoantigen expression correlated directly with the expression of muscle regeneration markers and correlated inversely with the expression of genes encoding mature muscle proteins. Myositis autoantigens were also expressed at high levels in cultured human muscle cells. CONCLUSION: Most myositis autoantigens are highly expressed during muscle regeneration, which may relate to the propagation of autoimmunity. However, factors other than overexpression of specific autoantigens are likely to govern the development of unique autoantibodies in individual patients with myositis.
Authors: Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras Journal: Bioinformatics Date: 2012-10-25 Impact factor: 6.937
Authors: Andrew L Mammen; Tae Chung; Lisa Christopher-Stine; Paul Rosen; Antony Rosen; Kimberly R Doering; Livia A Casciola-Rosen Journal: Arthritis Rheum Date: 2011-03
Authors: Albert Selva-O'Callaghan; Iago Pinal-Fernandez; Ernesto Trallero-Araguás; José César Milisenda; Josep Maria Grau-Junyent; Andrew L Mammen Journal: Lancet Neurol Date: 2018-09 Impact factor: 44.182
Authors: Steven A Greenberg; Jack L Pinkus; Geraldine S Pinkus; Travis Burleson; Despina Sanoudou; Rabi Tawil; Richard J Barohn; David S Saperstein; Hannah R Briemberg; Maria Ericsson; Peter Park; Anthony A Amato Journal: Ann Neurol Date: 2005-05 Impact factor: 10.422
Authors: Andrew L Mammen; Livia A Casciola-Rosen; John C Hall; Lisa Christopher-Stine; Andrea M Corse; Antony Rosen Journal: Arthritis Rheum Date: 2009-12
Authors: David R Amici; Iago Pinal-Fernandez; Davi A G Mázala; Thomas E Lloyd; Andrea M Corse; Lisa Christopher-Stine; Andrew L Mammen; Eva R Chin Journal: Acta Neuropathol Commun Date: 2017-03-22 Impact factor: 7.801
Authors: Andrew L Mammen; Livia Casciola-Rosen; Lisa Christopher-Stine; Thomas E Lloyd; Kathryn R Wagner Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-11-19
Authors: David R Amici; Iago Pinal-Fernandez; Lisa Christopher-Stine; Andrew L Mammen; Marc L Mendillo Journal: Acta Neuropathol Date: 2021-09-09 Impact factor: 17.088
Authors: Nickie Seto; Jose Jiram Torres-Ruiz; Carmelo Carmona-Rivera; Iago Pinal-Fernandez; Katherine Pak; Monica M Purmalek; Yuji Hosono; Catia Fernandes-Cerqueira; Prateek Gowda; Nathan Arnett; Alexander Gorbach; Olivier Benveniste; Diana Gómez-Martín; Albert Selva-O'Callaghan; José C Milisenda; Josep M Grau-Junyent; Lisa Christopher-Stine; Frederick W Miller; Ingrid E Lundberg; J Michelle Kahlenberg; Adam I Schiffenbauer; Andrew Mammen; Lisa G Rider; Mariana J Kaplan Journal: JCI Insight Date: 2020-02-13
Authors: Spyridon Megremis; Thomas D J Walker; Xiaotong He; James O'Sullivan; William E R Ollier; Hector Chinoy; Neil Pendleton; Antony Payton; Lynne Hampson; Ian Hampson; Janine A Lamb Journal: Commun Biol Date: 2021-03-26
Authors: Jose C Milisenda; Iago Pinal-Fernandez; Thomas E Lloyd; Josep María Grau; Frederick W Miller; Albert Selva-O'Callaghan; Lisa Christopher-Stine; Werner Stenzel; Andrew L Mammen; Andrea M Corse Journal: Clin Exp Rheumatol Date: 2020-09-01 Impact factor: 4.862